Drug Profile
ARC AAT
Alternative Names: ARC-AATLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Arrowhead Research Corporation
- Developer Arrowhead Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alpha 1-antitrypsin deficiency
Most Recent Events
- 02 Dec 2016 Arrowhead Pharmaceuticals withdraws prior to enrolment a phase II trial in Alpha 1-antitrypsin deficiency in Sweden, Italy, Ireland and Canada (IV) (NCT02900183)
- 29 Nov 2016 Discontinued - Phase-I for Alpha 1-antitrypsin deficiency in Australia, Germany, Netherlands and United Kingdom (IV) due to company shifting its focus on on the development of RNAi therapeutics utilising its subcutaneous (subQ) and extra-hepatic delivery systems
- 29 Nov 2016 Discontinued - Phase-II for Alpha 1-antitrypsin deficiency in Sweden, Canada, Italy, Ireland (IV) due to company shifting its focus on on the development of RNAi therapeutics utilising its subcutaneous (subQ) and extra-hepatic delivery systems